Log in for full access to this activity, if you are registered.

Registration Options

ACPE credit is no longer available for this course but you can still access the course resources by signing in. Please look for other products in CPNP University.

Target Audience

This activity is designed for pharmacists and other health care professionals interested in expanding Overdose Education and Naloxone Distribution (OEND) at their practice site.

Session Summary

Prescription drug and opioid overdoses continue to rise in the U.S. Communities with Overdose Education and Naloxone Distribution (OEND) programs have demonstrated how effective this practice can be in the number of lives reported to have been saved. Legislation to allow access to naloxone for non-medical people has also been passed by many states. Since naloxone remains a prescription medication, pharmacists have an important role in facilitating access to this potentially life-saving medication. Many pharmacists are already incorporating OEND into their practice, but opportunities for expanding OEND practice remain. Expert presenters will present the various models they have implemented to increase Naloxone distribution within their practice setting.

Course Requirements

You will proceed through the following steps to satisfactorily complete this course:

  • Review the full content of the activity and reflect upon its teachings.
  • Complete the evaluation after participating/viewing the webinar. (login first)
  • Complete the post-test at the end of the activity no later than the closing activity date. (login first)
  • If necessary, complete the post-test retest no later than the closing activity date. (login first)
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (login first)

This course is provided online at cpnp.org and consists of the speaker audio and slides. A PDF file of the slides is also provided and access is available to participants indefinitely although ACPE credit is available only through the course expiration date.

Participants in this course must complete an examination and achieve a score of 70% or greater. Successful completion of the course also requires the completion of a course evaluation. ACPE statements of credit can be retrieved by participants online at cpnp.org immediately upon successful completion of the course.

Faculty Information and Disclosures

Jeffrey Bratberg, PharmD, BCPS
James Gasper, PharmD, BCPP
Theodore Pikoulas, PharmD, BCPP
Shannon Saldana, RPh, MS, PharmD, BCPP
Christopher Stock, PharmD, BCPP

View biographical information and disclosures

Learning Objectives

  1. Identify a model for overdose education and naloxone distribution (OEND) that is most applicable to their practice setting.
  2. Summarize patient overdose education (OE) elements that will fit best in their practice setting.
  3. Describe strategies to bill an insurance carrier for OEND in their practice setting.
  4. Describe strategies to overcome some of the barriers to developing OEND in their practice setting.

Continuing Education Credit and Disclosures

Webinar Date: The live webinar has already finished
Activity Dates: 08/13/2015 - 08/13/2016
ACPE Contact Hours: 1.0
ACPE Number: 0284-0000-15-078-H04-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This self-study course provides 1.0 contact hours (0.01 CEUs) of knowledge-based continuing education credit from CPNP approved programming. The ACPE universal program number assigned to this course is 0284-0000-15-078-H04-P (1.0 contact hours).

Grant Support

This activity is supported by the American Academy of Addiction Psychiatry under its prime grant from the Substance Abuse and Mental Health Services Administration. Funding for this initiative was made possible (in part) by Providers’ Clinical Support System for Opioid Therapies (grant no. 1H79TI025595) from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.